Skip to main content

Supplementary Figure 2 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma

Publication ,  Other
Abou-Alfa, GK; Geyer, SM; Nixon, AB; Innocenti, F; Shi, Q; Kumthekar, P; Jacobson, S; El Dika, I; Yaqubie, A; Lopez, J; Huang, B; Tang, Y-W ...
March 7, 2024

<p>Supplementary Figure 2. Tile plots of HCV viral ჼ00ter levels over ჼ00me for paჼ00ents treated with Doxorubicin and Sorafenib (A) or Sorafenib alone (B). For sample collected at the progression ჼ00me point, the ჼ00ming of progression is reflected as text in that ჼ00le.</p>

Duke Scholars

DOI

Publication Date

March 7, 2024
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Abou-Alfa, G. K., Geyer, S. M., Nixon, A. B., Innocenti, F., Shi, Q., Kumthekar, P., … Venook, A. P. (2024). Supplementary Figure 2 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma. https://doi.org/10.1158/2767-9764.25359915

DOI

Publication Date

March 7, 2024